Cystatin C, a Controversial Biomarker in Hypothyroid Patients under Levothyroxine Therapy: THYRenal, a Pilot Cohort Observational Study
Abstract
:1. Introduction
2. Materials and Methods
Statistical Analysis
3. Results
3.1. Comparison between L-T4 Treated Hypothyroid Patients Reaching Optimal vs. Suboptimal TSH Therapeutic Targets
3.2. Correlation Analyses between Renal Functional Parameters
3.3. Correlation Analyses between TSH and Renal Functional Parameters
3.4. Statistical Measures Linking Serum Cys-C to Medical Diagnosis of Hypothyroid Patients with Suboptimal TSH Target
4. Discussion
5. Conclusions
Author Contributions
Funding
Conflicts of Interest
References
- Mohamedali, M.; Maddika, S.R.; Vyas, A.; Viswanathan, I.; Pramil, C. Thyroid disorders and chronic kidney disease. Int. J. Nephrol. 2014, 2014, 520281. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Mariani, L.H.; Berns, J.S. The renal manifestations of thyroid disease. J. Am. Soc. Nephrol. 2012, 23, 22–26. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Zoccali, C.; Mallamaci, F. Thyroid function and clinical outcomes in kidney failure. Clin. J. Am. Soc. Nephrol. 2012, 7, 12–14. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Iglesias, P.; Díez, J.J. Thyroid dysfunction and kidney disease. Eur. J. Endocrinol. 2009, 160, 503–515. [Google Scholar] [CrossRef] [PubMed]
- Bradley, S.E.; Stéfan, F.; Coelho, J.B.; Réville, P. The thyroid and the kidney. Kidney Int. 1974, 6, 346–365. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Cantone, A.; Wang, T.; Pica, A.; Simeoni, M.; Capasso, G. Use of transgenic mice in acid-base balance studies. J. Nephrol. 2006, 19, S121–S127. [Google Scholar]
- Simeoni, M.; Damiano, S.; Capolongo, G.; Trepiccione, F.; Zacchia, M.; Fuiano, G.; Capasso, G. Rare renal diseases can be used as tools to investigate common kidney disorders. Kidney Dis. 2017, 3, 43–49. [Google Scholar] [CrossRef]
- Vargas, F.; Rodrìguez-Gòmez, I.; Vargas-Tendero, P.; Jimenez, E.; Montiel, M. The renin-angiotensin system in thyroid disorders and its role in cardiovascular and renal manifestations. J. Endocrinol. 2012, 213, 25–36. [Google Scholar] [CrossRef] [Green Version]
- Simeoni, M.; Nicotera, R.; Colao, M.; Citraro, M.L.; Pelagi, E.; Cerantonio, A.; Comi, N.; Coppolino, G.; Fuiano, G. Direct inhibition of plasmatic renin activity with aliskiren: A promising but under-investigated therapeutic option for non-diabetic glomerulonephritis. Int. Urol. Nephrol. 2015, 48, 229–237. [Google Scholar] [CrossRef]
- Cianfrone, P.; Simeoni, M.; Comi, N.; Piraina, V.; Talarico, R.; Cerantonio, A.; Gentile, I.; Fabiano, F.F.; Lucisano, G.; Foti, D.; et al. How to improve duration and efficiency of the antiproteinuric response to Ramipril: RamiPROT, a prospective cohort study. J. Nephrol. 2017, 30, 95–102. [Google Scholar] [CrossRef]
- Simeoni, M.; Armeni, A.; Summaria, C.; Cerantonio, A.; Fuiano, G. Current evidence on the use of anti-RAAS agents in congenital or acquired solitary kidney. Ren. Fail. 2017, 39, 660–670. [Google Scholar] [CrossRef] [PubMed]
- Rhee, C.M.; Kalantar-Zadeh, K.; Streja, E.; Carrero, J.J.; Ma, J.Z.; Lu, J.L.; Kovesdy, C.P. The relationship between thyroid function and estimated glomerular filtration rate in patients with chronic kidney disease. Nephrol. Dial. Transplant. 2014, 30, 282–287. [Google Scholar] [CrossRef] [PubMed]
- Katz, A.I.; Emmanouel, D.S.; Lindheimer, M.D. Thyroid hormone and the kidney. Nephron 1975, 15, 223–249. [Google Scholar] [CrossRef] [PubMed]
- Gheissari, A.; Hashemipour, M.; Khosravi, P.; Adibi, A. Different aspects of kidney function in well-controlled congenital hypothyroidism. J. Clin. Res. Pediatr. Endocrinol. 2012, 4, 193–198. [Google Scholar] [CrossRef]
- Simeoni, M.; Cerantonio, A.; Pastore, I.; Liguori, R.; Greco, M.; Foti, D.; Gulletta, E.; Brunetti, A.; Fuiano, G. The correct renal function evaluation in patients with thyroid dysfunction. J. Endocrinol. Investig. 2016, 39, 495–507. [Google Scholar] [CrossRef]
- Sun, M.T.; Hsiao, F.C.; Su, S.C.; Pei, D.; Hung, Y.J. Thyrotropin as an independent factor of renal function and chronic kidney disease in normoglycemic euthyroid adults. Endocr. Res. 2012, 37, 110–116. [Google Scholar] [CrossRef]
- Shin, D.H.; Lee, M.J.; Lee, H.S.; Oh, H.J.; Ko, K.I.; Kim, C.H.; Doh, F.M.; Koo, H.M.; Kim, H.R.; Han, J.H.; et al. Thyroid hormone replacement therapy attenuates the decline of renal function in chronic kidney disease patients with subclinical hypothyroidism. Thyroid 2013, 23, 654–661. [Google Scholar] [CrossRef]
- Jaygopal, V.; Keevil, B.G.; Atkin, S.L. Paradoxical changes in cystatin C and serum creatinine in patients with hypo- and hyperthyroidism. Clin. Chem. 2009, 49, 680–681. [Google Scholar] [CrossRef]
- Manetti, L.; Pardini, E.; Genovesi, M.; Campomori, A.; Grasso, L.; Morselli, L.L.; Lupi, I.; Pellegrini, G.; Bartalena, L.; Bogazzi, F.; et al. Thyroid function differently affects serum cystatin C and creatinine concentrations. J. Endocrinol. Investig. 2005, 28, 346–349. [Google Scholar] [CrossRef]
- Stojanoski, S.; Gjorceva, D.P.; Gruev, T.; Ristevska-Miceva, S.; Ristevska, N. Impact of Thyroid Dysfunction on Serum Cystatin C, Serum Creatinine and Glomerular Filtration Rate. Maced. J. Med. Sci. 2011, 4, 25–30. [Google Scholar]
- Wiesli, P.; Schwegler, B.; Spinas, G.A.; Schmid, C. Serum cystatin C is sensitive to small changes in thyroid function. Clin. Chim. Acta 2003, 338, 87–90. [Google Scholar] [CrossRef] [PubMed]
- Biondi, B.; Wartofsky, L. Treatment with thyroid hormone. Endocr. Rev. 2014, 35, 433–512. [Google Scholar] [CrossRef] [PubMed]
- Razvi, S.; Bhana, S.; Mrabeti, S. Challenges in interpreting Thyroid Stimulating Hormone results in the diagnosis of thyroid dysfunction. J. Thyroid Res. 2019, 2019, 4106816. [Google Scholar] [CrossRef] [PubMed]
- McAninch, E.A.; Rajan, K.B.; Miller, C.H.; Bianco, A.C. Systemic thyroid hormone status during Levothyroxine therapy in hypothyroidism: A systematic review and meta-analysis. J. Clin. Endocrinol. Metab. 2018, 103, 4533–4542. [Google Scholar] [CrossRef] [PubMed]
- Briesacher, B.A.; Andrade, S.E.; Fouayzi, H.; Chan, K.A. Comparison of drug adherence rates among patients with seven different medical conditions. Pharmacotherapy 2008, 28, 437–443. [Google Scholar] [CrossRef]
- Laterza, O.F.; Price, C.P.; Scott, M.G. Cystatin C: An Improved Estimator of Glomerular Filtration Rate? Clin. Chem. 2002, 48, 699–707. [Google Scholar] [CrossRef] [Green Version]
- Grubb, A. Cystatin is indispensable for evaluation of kidney disease. EJIFCC 2017, 28, 268–276. [Google Scholar]
- Dharnidharka, V.R.; Knon, C.; Stevens, G. Serum cystatin C is superior to serum creatinine as a marker of kidney function: A meta-analysis. Am. J. Kidney Dis. 2002, 40, 221–226. [Google Scholar] [CrossRef]
- Coll, E.; Botey, A.; Alvarez, L.; Poch, E.; Quinto, L.; Saurina, A.; Vera, M.; Piera, C.; Darnell, A. Serum cystatin C as a new marker for noninvasive estimation of glomerular filtration rate and as a marker for early renal impairment. Am. J. Kidney Dis. 2000, 36, 29–34. [Google Scholar] [CrossRef]
- Gupta, S.; Verma, M.; Gupta, A.K.; Kaur, A.; Kaur, V.; Singh, K. Are we using Thyroid Function Tests Appropriately? Indian J. Clin. Biochem. 2011, 26, 178–181. [Google Scholar] [CrossRef] [Green Version]
- Fricker, M.; Wiesli, P.; Brändle, M.; Schwegler, B.; Schmid, C. Impact of thyroid dysfunction on serum Cystatin C. Kidney Int. 2003, 63, 1944–1947. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- KDIGO 2012 Clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2013, 3, 5–14.
- Spanaus, K.-S.; Kollerits, B.; Ritz, E.; Hersberger, M.; Kronenberg, F.; von Eckerstein, A. Serum creatinine, cystatin C, and beta-trace protein in diagnostic staging and predicting progression of primary nondiabetic chronic kidney disease. Clin. Chem. 2010, 56, 740–749. [Google Scholar] [CrossRef] [PubMed]
- Ye, Y.; Gai, X.; Xie, H.; Jiao, L.; Zhang, S. Impact of thyroid function on serum cystatin C and estimated glomerular filtration rate: A cross-sectional study. Endocr. Pract. 2013, 19, 393–403. [Google Scholar] [CrossRef] [PubMed]
- Randers, E.; Erlandler, E.J.; Pedersen, O.L.; Hasling, C.; Danielsen, H. Serum cystatin C as an endogenous parameter of the renal function in patients with normal to moderately impaired kidney function. Clin. Nephrol. 2000, 54, 203–209. [Google Scholar]
- Filler, G.; Bökenkamp, A.; Hofmann, W.; Le Bricon, T.; Martínez-Brú, C.; Grubb, A. Cystatin C as a marker of GFR—History, indications, and future research. Clin. Biochem. 2005, 38, 1–8. [Google Scholar] [CrossRef]
- Chew, J.S.C.; Saleem, M.; Florkowski, C.M.; George, P.M. Cystatin C—A paradigm of evidence based laboratory medicine. Clin. Biochem. Rev. 2008, 29, 47–62. [Google Scholar]
- Benoit, S.W.; Ciccia, E.A.; Devarajan, P. Cystatin C as a biomarker of chronic kidney disease: Latest developments. Exp. Rev. Mol. Diagn. 2020. [Google Scholar] [CrossRef]
- Pucci, L.; Triscornia, S.; Lucchesi, D.; Fotino, C.; Pellegrini, G.; Pardini, E.; Miccoli, R.; Del Prato, S.; Penno, G. Cystatin C and estimates of renal function: Searching for a better measure of kidney function in diabetic patients. Clin. Chem. 2007, 53, 480–488. [Google Scholar] [CrossRef] [Green Version]
- Asvold, B.O.; Bjoro, T.; Vatten, L. Association of thyroid function with estimated glomerular filtration rate in a population-based study: The HUNT study. Eur. J. Endocrinol. 2011, 164, 101–105. [Google Scholar] [CrossRef] [Green Version]
- McDermott, M.T.; Ridgway, E.C. Subclinical hypothyroidism is mild thyroid failure and should be treated. J. Clin. Endocrinol. Metab. 2001, 86, 4585–4590. [Google Scholar] [CrossRef] [PubMed]
Study Cohort | |
---|---|
Race | Caucasian |
N | 84 (56 ♀–28 ♂) |
Age (yrs) | 53 ± 8.5 |
BMI (kg/m2) | 28.76 ± 3.3 |
Systolic blood pressure (mm Hg) | 123 ± 10.2 |
Diastolic blood Pressure (mm Hg) | 75 ± 8.8 |
TSH (μIU/mL) | 1.9 ± 1.0 |
FT3 (pg/mL) | 3.23 ± 0.3 |
FT4 (ng/dL) | 1.33 ± 0.2 |
Creatinine (mg/dL) | 0.74 ± 0.1 |
mGFR (mL/min/1.73 m2) | 115 ± 16.6 |
CKD-EPI eGFR (mL/min/1.73 m2) | 99 ± 8.8 |
Cystatin C (mg/L) | 0.97 ± 0.4 |
Patients with Optimal TSH | Patients with Suboptimal TSH | p | |
---|---|---|---|
N | 54 (36 ♀–18 ♂) | 30 (20 ♀–10 ♂) | |
Age (yrs) | 53 ± 8.5 | 51 ± 8.4 | 0.208 |
BMI (kg/m2) | 28.29 ± 3.1 | 29.59 ± 3.5 | 0.087 |
Systolic blood pressure (mm Hg) | 127 ± 9.7 | 117 ± 8.4 | <0.0001 |
Diastolic blood Pressure (mm Hg) | 75 ± 8.3 | 72 ± 7.5 | 0.038 |
TSH (μIU/mL) | 1.28 ± 0.4 | 3.10 ± 0.6 | <0.0001 |
FT3 (pg/mL) | 3.24 ± 0.3 | 3.22 ± 0.4 | 0.821 |
FT4 (ng/dL) | 1.32 ± 0.2 | 1.34 ± 0.2 | 0.716 |
Creatinine (mg/dL) | 0.74 ± 0.1 | 0.75 ± 0.1 | 0.730 |
mGFR (mL/min/1.73 m2) | 113 ± 15.2 | 119 ± 18.6 | 0.125 |
CKD-EPI eGFR (mL/min/1.73 m2) | 98 ± 7.2 | 102 ± 11.03 | 0.076 |
Cystatin C (mg/L) | 0.77 ± 0.1 | 1.34 ± 0.5 | <0.0001 |
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Greco, M.; Foti, D.P.; Aversa, A.; Fuiano, G.; Brunetti, A.; Simeoni, M. Cystatin C, a Controversial Biomarker in Hypothyroid Patients under Levothyroxine Therapy: THYRenal, a Pilot Cohort Observational Study. J. Clin. Med. 2020, 9, 2958. https://0-doi-org.brum.beds.ac.uk/10.3390/jcm9092958
Greco M, Foti DP, Aversa A, Fuiano G, Brunetti A, Simeoni M. Cystatin C, a Controversial Biomarker in Hypothyroid Patients under Levothyroxine Therapy: THYRenal, a Pilot Cohort Observational Study. Journal of Clinical Medicine. 2020; 9(9):2958. https://0-doi-org.brum.beds.ac.uk/10.3390/jcm9092958
Chicago/Turabian StyleGreco, Marta, Daniela Patrizia Foti, Antonio Aversa, Giorgio Fuiano, Antonio Brunetti, and Mariadelina Simeoni. 2020. "Cystatin C, a Controversial Biomarker in Hypothyroid Patients under Levothyroxine Therapy: THYRenal, a Pilot Cohort Observational Study" Journal of Clinical Medicine 9, no. 9: 2958. https://0-doi-org.brum.beds.ac.uk/10.3390/jcm9092958